Skip to main content

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Active, not recruiting · Phase 3 · NCT03432286

Conditions: Episodic Migraine

At a glance

Research payments reported, 2025
$1.2M
U.S. investigators named
28
Sites paid
37
Planned or actual enrollment
533

About the trial

Sponsor
Eli Lilly and Company
Tested
Galcanezumab (drug), Placebo (drug)
Dates
Started 2018-03-14; completion 2026-11
Results posted
Not yet

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.

From ClinicalTrials.gov, last updated 2026-01-26. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $1.2M in research payments for this study in 2025 (59 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Rehabilitation & Neurological Services, Ll $180,307
  • Cincinnati Children's Hospital Medical Center, OH $169,794
  • Ezy Medical Research Co $152,881
  • Medical Research PArtners $107,097
  • Dr Samuel Sanchez Psc $71,965
  • Minneapolis Clinic of Neurology $65,064
  • Children's Hospital Colorado, CO $62,696
  • Memorial Health Services $56,858
  • Headlands Horizons LLC $55,277
  • Pensacola Research Consultants Inc $47,076
  • Seattle Children's Hospital, WA $41,971
  • Ponce School of Medicine $29,495
  • Northwest Clinical Trials Inc $27,236
  • University of Kentucky Research Foundation $23,658
  • Univ of South Florida Rsrch Foundation $21,776
  • Velocity Clinical Research Inc $17,656
  • Medvadis Research Corp LLC $11,411
  • Neurology Associates of Tucson $9,739
  • Tribe Clinical Research LLC $9,204
  • University of Miami $9,084
  • Feinstein Institute for Medical $6,560
  • Alexian Brothers Health System $5,882
  • Children's of Alabama $5,200
  • Providence St Vincent Medical Center, OR $4,800
  • Long Beach Ctr for Clinical Research $2,779
  • Tennessee Oncology PLLC $1,943
  • Encephalogic Medical Group Inc $1,260
  • Pcrs Network LLC $1,186
  • Alexian Brothers Hospital Network $1,067
  • University of North Carolina at Chapel Hill $1,014
  • Pharmasite Research Inc $832
  • University of Kentucky Hospital, KY $792
  • Mountain View Clinical Research Inc $724
  • Clinical Neuroscience Solutions DBA Cns Hlthcare $600
  • St Josephs Hospital and Medical Center $500
  • Omega Research Consultants LLC $150
  • New Horizon Research Center $100

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.